1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
Europe Gastrointestinal Drugs Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Drug Class ; Route of Administration ; Application ; and Distribution Channel, and Country

Europe Gastrointestinal Drugs Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Drug Class ; Route of Administration ; Application ; and Distribution Channel, and Country

  • November 2020
  • 155 pages
  • ID: 5999683
  • Format: PDF
  • The Insight Partners
Up to $1000 off Until Mar 10th 2021

Summary

Table of Contents

Search Inside

The Europe gastrointestinal drugs market is expected to reach US$ 17,810.81 million by 2027 from US$ 12,721.85 million in 2019; it is expected to grow at a CAGR of 4.4% from 2020 to 2027. Rising prevalence of gastrointestinal (GI) diseases and increase in development of biologics are expected to boost the growth of the market. However, factors such as low awareness associated with gastrointestinal disorders in low-income economies are likely to restrain the growth of the market. Additionally, increasing investment in research activities coupled with growing pipeline of GI candidates and emergence of biosimilars are likely to fuel the growth of the gastrointestinal drugs market during the forecast period.
Gastrointestinal disorders are medical conditions related to the digestive system that affect the colon, small and large intestine, and rectum.The disorders include constipation, irritable bowel, ulcerative colitis (UC), and peptic ulcer diseases.

These disorders are characterized by various symptoms such as pain, bloating, diarrhea, nausea, and vomiting.These disorders constitute a large proportion of outpatients and frequent hospital visits.

A wide range of GI drugs is commercially available in the market for the treatment of various conditions. Additionally, rising investments in the development of biologics and emergence of biosimilars are expected to drive the market during the forecast period.
Increasing development of biologics for the treatment of GI diseases is driving the market.In the last few years, new treatments called biologics were being used for the treatment of inflammatory diseases.

Currently, the FDA has approved Humira, Cimzia, Remicade, Simponi, Tysabri, and Entyvio biologics for the treatment of Crohn’s disease and ulcerative colitis.Biologics have revolutionized the inflammatory bowel disease (IBD), treatment, and their success in the treatment of these indications is driving the use of biologics in other GI conditions, such as celiac disease, eosinophilic esophagitis, and autoimmune hepatitis.

The development of new medication is driving the market.For instance, in September 2019, Janssen Pharmaceutical received the European Commission approval for STELARA.

It would be used in the treatment of moderately to severely active ulcerative colitis in adults. It is the first biologic treatment that would target the IL-12/IL-23 pathway, an important therapeutic target in UC. Apart from this, strategic initiatives by market players, such as product launch in untapped markets, are further driving the market. The introduction of new biologics is expected to fuel the market growth during the forecast period.
Along with product launches, the market players are carrying out different strategies to add innovative therapies in their product portfolio.This is further boosting the growth of the gastrointestinal drugs market.

Many people are living with celiac disease, and they manage their symptoms by following a gluten-free diet. There is still no treatment for people who experience severe symptoms.
The European economy is severely affected due to the exponential growth of COVID-19 cases in the region.Short-term impacts of COVID-19 pandemic include demand changes, revision in regulatory process, changes in research and development process and shift toward telecommunication and telemedicine.

However, growing awareness about gastrointestinal products available in market in Europe is likely to boost the demand for constipation drug products and supply in COVID-19 pandemic, hence, it can boost the growth of the gastrointestinal drugs market.
In 2019, the acid neutralizers segment accounted for the highest share of the market.However, the biologics segment is expected to be the fastest-growing segment during the forecast period.

The biologics segment is anticipated to register the highest CAGR during the forecast period. The growth of the segment is attributed to growing product development and increasing product launches in the market.
A few of the major secondary sources associated with the Europe gastrointestinal drugs market report are World Health Organization, European Federation of Crohn’s & Ulcerative Colitis Associations, Centers of Disease Control and Prevention, International Foundation for Gastrointestinal Disorders, and National Institute of Health.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off

$3000

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

North America Gastrointestinal Drugs Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Drug Class ; Route of Administration ; Application ; and Distribution Channel, and Country

  • $ 3000
  • November 2020
  • 133 pages

Market Introduction Gastrointestinal drugs include promotility drugs, antimotility drugs, and drugs for acid-related disorders.The generally used gastrointestinal drugs as a group are considered safe. ...

  • North America
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Industry analysis
  • Drug Approval
  • Use Of Prescription Drugs

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on